Government’s savings on Australia’s PBS far outweighs investment in new medicines

31 March 2015
australia-big

Analyses released yesterday and today show that the Australian government will achieve more than A$16 billion ($12.4 billion) in Pharmaceutical Benefits Scheme (PBS) savings from 2010-18, whilst listings of new medicines over this period will cost only A$6 billion.

The analysis conducted by PharmaDispatch, translates to government savings of more than A$2.70 for every A$1 spent on new medicines between 2010 and 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical